Updated:
Princeton BioPharma Capital Partners
Princeton Biopharma Capital Partners is a private equity firm that invests in commercial stage healthcare companies. It has made six investments to date.
Overview
Princeton Biopharma Capital Partners is a private equity firm that invests in commercial stage healthcare companies. It has made six investments to date. The firm's most recent investment was in Fidelis Animal Health as part of its Series A funding transaction on July 21, 2021.
General information
Firm type
Private Equity
Year founded
2010
Location
Region
North America
Country
United States
City
Bridgewater
Corporate office
Bridgewater, NJ, United States
Sector focus
Frequently asked questions
What investment stages does Princeton BioPharma Capital Partners target?
Per the firm's own strategy description, Princeton BioPharma covers four distinct stages: early-stage startups, growth equity, corporate divestitures, and restructurings. This spans pre-revenue platforms through mature carve-outs from large pharmaceutical companies. The common thread across stages is transitional complexity — companies moving between ownership structures, regulatory phases, or commercial maturity levels that require more than passive capital.
What is the firm's geographic investment focus?
The firm invests primarily in the Mid-Atlantic and Northeastern United States, where the highest concentration of pharmaceutical companies, academic medical centers, and FDA-registered manufacturing facilities is located. This regional concentration supports the hands-on operational model required for transitional life-science investing. No international mandate has been disclosed.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: